Will Walmart cover Ozempic and Mounjaro at no cost for employees by 27 October 2026?

probability 86% deadline 2026-10-27 (13d left) Finance

Posted 2026-10-13 — 14 days before the deadline, stated before the outcome.

Walmart is a major American retail corporation that provides health insurance benefits to its workforce. Prescription drug coverage policies often include specific lists of medications and cost-sharing structures for employees.

The claim

Walmart formally implements a benefits policy covering at least 250 prescription medications, including Ozempic and Mounjaro, at no out-of-pocket cost for eligible employees by 27 October 2026.

Reasoning trace

CEO/Chief People Officer public commitment via staff memo and media reports
Strategic alignment with retention goals in competitive retail labor market
Immediate operational feasibility using existing insurance infrastructure

Evidence so far

3 confirming · 0 denying signals · 1 verified · 2 broken assumptions. The evidence itself is part of the full dossier.

Probability history

Updated 2 times since mint (last on 2026-10-14) — 81% at mint → 86% today.

What to watch

precondition Walmart's health insurance carrier publishes a public notice or press release confirming the addition of at least 250 prescription medications, including Ozempic and Mounjaro, to the Walmart employee formulary with $0 copay coverage. contradicted
leading indicator Walmart issues a public statement or press release confirming the partnership with its insurer to expand the prescription drug formulary observed
leading indicator Walmart's Chief People Officer or CEO issues a public media statement or interview confirming the implementation of the expanded prescription benefits package for employees.

The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].

Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.